One of the most recent lawsuits was filed by Michael C., a man from Ohio who developed bladder cancer after years of taking Zantac (150-mg) tablets every day from 2014 through 2017.
The lawsuit blames his diagnosis on the carcinogenic chemical N-Nitrosodimethylamine (NDMA), an impurity that is left over from the industrial processes used to make Zantac and ranitidine.
A growing number of Zantac lawsuits have been filed by people who were diagnosed with bladder cancer, stomach cancer, colorectal cancer, esophageal cancer and other cancers along the digestive tract.
The lawsuit was filed on November 14, 2019 in the U.S. District Court for the District of New Jersey — Case No. 3:19-cv-20289.
A slew of recalls have been issued after the online pharmacy Valisure discovered that some Zantac tablets contain up to 29,000 times the FDA’s daily recommended limit of NDMA.
Walmart, CVS, Rite Aid, Target, Walgreens and many other pharmacies also suspended sales of Zantac and ranitidine due to unacceptable levels of NDMA in the medications.
On November 19, Precision Dose Inc. recalled 4 lots of ranitidine oral solution (150-mg/10-mL) in response to a separate recall by the manufacturer, Amneal Pharmaceuticals. LLC.
On November 15, GSMS Inc. recalled ranitidine HCl 150-mg and 300-mg capsules, which were primarily sold to Amerisource Bergen, McKesson, and Tricare Mail Order Pharmacies (TMOP).